Corcept Therapeutics’ (CORT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Corcept Therapeutics (NASDAQ:CORT) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $115.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.73 EPS and FY2029 earnings at $8.52 EPS.

Other research analysts also recently issued reports about the company. StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics has an average rating of “Buy” and a consensus price target of $99.75.

Corcept Therapeutics Price Performance

Shares of CORT stock opened at $59.85 on Thursday. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $75.00. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $59.60 and a two-hundred day simple moving average of $51.16. The stock has a market capitalization of $6.27 billion, a price-to-earnings ratio of 47.50 and a beta of 0.58.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. On average, analysts predict that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider Sean Maduck sold 20,000 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the transaction, the insider now owns 85,318 shares in the company, valued at approximately $4,299,174.02. This represents a 18.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $50.54, for a total transaction of $111,188.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,600 shares of company stock worth $1,399,576. 20.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Creative Planning raised its position in Corcept Therapeutics by 7.2% during the third quarter. Creative Planning now owns 12,467 shares of the biotechnology company’s stock valued at $577,000 after acquiring an additional 841 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Corcept Therapeutics during the 3rd quarter worth approximately $238,000. Nisa Investment Advisors LLC increased its holdings in shares of Corcept Therapeutics by 83.5% during the 3rd quarter. Nisa Investment Advisors LLC now owns 9,851 shares of the biotechnology company’s stock valued at $456,000 after purchasing an additional 4,483 shares in the last quarter. abrdn plc lifted its stake in shares of Corcept Therapeutics by 27.1% in the 3rd quarter. abrdn plc now owns 666,952 shares of the biotechnology company’s stock valued at $30,867,000 after purchasing an additional 142,310 shares during the period. Finally, US Bancorp DE boosted its holdings in Corcept Therapeutics by 162.2% during the third quarter. US Bancorp DE now owns 19,683 shares of the biotechnology company’s stock worth $911,000 after buying an additional 12,177 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.